Dear Sir, Ferrannini et al. in their recent paper 'Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome' [1] suggested that Syndrome X variables occurred more frequently in association with each other than expected by chance in a large, mixed Caucasian and Mexican-American population, but their analysis over-represented the relationships.
Prevalence of obesity with hypertension = prevalence of obesity x prevalence of hypertension x complement Type 2 diabetes x Letters to the editor complement IGT x complement of raised triglycerides x complement of raised cholesterol. In addition, since Type 2 diabetes and IGT are mutually exclusive categories, these should be combined to give a prevalence of 20.4 % and complement of 79.6 %. Thus, by reference to Table 1 , the expected prevalence of obesity with hypertension is: = 0.543 x 0.098 x 0.7% x 0.897 x 0.908 = 0.034
These data are included in Table 1 and the paired associations appear closer to those expected by chance, although there was still a two-fold greater proportion with multiple associations than expected by chance.
An additional over-estimate of associations between Syndrome X variables arose from their choice of a "normal" control group. It was suggested that subjects with any one abnormal variable were more likely to have abnormalities of other variables. However, the control group was chosen as having by definition, no abnormality. Naturally, if this is regarded as 'normal', by definition the data for any variable will be greater in any population than in the "normal" population which is a consequence of the definition of the control group rather than a result. This definition of "normal" also leads to an additional potential bias in that their defined "normal" control group contained fewer Mexican-Americans than those who had abnormal variables (mean 57 % vs 71%, respectively) was younger (39.6 years vs 42.7 years, respectively) and less obese (22.8 vs 29.5 BMI kg. m-2, respectively).
The multivariate analyses showed greater differences between the abnormal and control groups for fasting plasma insulin ( + 36 %) and triglyceride ( + 50 %), than for other variables. These trends are probably real, but could have been exaggerated by the use of parametric statistics for variables that are usually log distributed, and multivariate statistics may not have been able to account adequately for differences in obesity between groups.
The authors imply hyperinsnlinaemia is a key feature of Syndrome X, but it is not clear whether this was a primary feature or was secondary to variables such as obesity and central obesity. In a similar analysis of newly-diagnosed Caucasian Type 2 diabetic subjects, who were not treated with hypotensive or hypoglycaemic agents, it appeared the majority of associations characterising Syndrome X were secondary to obesity and central obesityrather thanbeing a distinctive identifiable syndrome [2] . Exceptions were significant associations between log triglyceride and log insulin and inversely between log triglyceride and HDL-cholesterol. These could have arisen from specific metabolic defects rather than being part of a global "Syndrome X". This does not imply that variables included in Syndrome X do not have pathological consequences, but it is doubtful (i) whether a specific syndrome exists or (ii) whether obesity/central obesity rather than hyp erinsulin aemia are key features in the general population. Table 1 of their Letter. However, that the observed prevalence is lower than expected is still true for 11 of 14 paired associations;this discrepancy also applies to eachisolated condition, and the prevalence of multiple associations is invariably higher than expected by roughly two-fold. Thus, the conclusions we drew do not need to be changed at all. Note that we do not attach particular importance to these figures in absolute, as they are obviously influenced by the diagnostic criteria as well as the ethnic composition and constitutional characteristics of the population we sampled [1] . Rather, we emphasise the pattern of overlap of the six conditions examined.
(b) The second point concerns the choice of a "normal" control group, with which we partially disagree. That any variable in a disease group must be different from the control group as a matter of definition is not true for all variables but only for the coding variables. In our analysis, we considered 12 variables, of which only five (BMI, fasting and 2-h plasma glucose, serum total cholesterol and triglycerides) were classification variables. (Hypertension was defined on the basis of antihypertensive treatment rather than measured blood pressure values in 92 % of the cases). Therefore, the differences in the other seven variables between any of the disease groups and the control group were actual results, not consequences of the definition. For example, the presence of statistically significant hyperinsulinaemia, systolic hypertension, and high waist:hip ratio in all disease groups (Table 4 of our paper [1] ) is not implicit in the selection of the control group.
Incidentally, in these comparisons multiple regression analysis was employed to account for differences in age, ethnicity, and BMI, as stated in the legend to Tables 4 and 5 of our paper [1] . In addition, in all analyses the values of plasma insulin, glucose, and triglyceride levels were log transformed (this is stated in the Statistical analysis section), although the results were back transformed to calculate the percent differences between the insulin resistant and control groups in TaNes 4 and 5 [11. Thus, on these two latter points Dr. Turner and his colleagues have overlooked our presentation.
But the question, what is the appropriate 'control' for phenotypic characters (eg, plasma insulin concentrations) that have multiple determinants, is more general. Our way of presenting the data of the San Antonio Heart Study in our paper [1] was simply the 'discrete' equivalent of multivariate analysis: we chose categories over continuous variables only to compact and visualise the information.
To exemplify the equivalence of the two approaches, we present in Table 1 the multiple regression equations for fasting and 2-h plasma insulin and serum triglyceride concentrations in the whole database. Multivariate analysis indicates that fasting plasma insulin concentrations are significantly increased in association with obesity, impaired glucose tolerance, Type2 (non-insulin-dependent) diabetes mellitus, hypertension, and hypertriglyceridaemia independently of one another and after adjustment for age, gender, ethnicity and waist:hip ratio. These results are identical to those obtained with the categorical analysis presented in Table 4 of our paper [1] . In addition, if one calculates from the multiple regression equations in Table l the expected mean value of the dependent variables in an ideal "control" subject (ie, a subject with none of the diseases), the following figures result: 54 pmol/1 for fasting insulin, 330 pmol/1 for 2-h insulin, and 1.2 mmol/1 for serum triglycerides (at a mean age of 39.6 years, a mean waist: hip ratio of 0.848, and a 50 % prevalence (Tables 2 and 3 of our paper [1] ).
(c) The final point concerns the possibility that we overestimated the prevalence of Syndrome X. The purpose of our analysis was not, however, to prove the existence and gauge the frequency of Syndrome X. We simply showed that, if one takes a pool of individuals in the general population including obese, diabetic, glucose intolerant, hypertensive, and dyslipidaemic subjects, essentially similar metabolic profiles are recovered whichever categorical abnormality is used to enter the pool. One common change (or key feature, as we titled the paper) in the duster is the presence of hyperinsulinaemia (and, by inference, insulin resistance). We did not mean to imply that hyperinsulinaemia is the causative factor in this insulin resistant pool of individuals. Although, as Dr. Turner and colleagues say, hyperinsulinaemia can have pathological consequences, the analysis of cross-sectional observations cannot provide any evidence that high insulin levels (or any other variable, for that matter) play a causal role in the appearance of the cluster of abnormalities.
As defined by Reaven [2] , Syndrome X is the simultaneous presence of diagnostic glucose intolerance, high blood pressure, and dyslipidaemia (high VLDL triglycerides and low HDL cholesterol). By using this definition, the prevalence of Syndrome X in our database is only 0.24% in lean persons, and 1.2% in obese individuals. Fasting plasma insulin levels are 145 and 250 pmol/1, respectively in lean and obese Syndrome X patients, while the corresponding 2-h plasma insulin values are 870 and 1,265 pmol/1. Thus, this Syndrome X is indeed characterised by rather extreme hyperinsulinaemia (Table 3 of our paper [1] ) whether it occurs in lean or obese subjects. If, on the other hand, we define the syndrome as the presence of at least one diagnostic abnormality (e. g. diabetes or hypertension), we showed [1] that the syndrome will most often manifest itself with a constellation of clinical and subclinical changes in glucose tolerance, blood pressure, and lipid metabolism. The prevalence of such a primary insulin resistance syndrome can be estimated (in our database) to range between 8 and 10% of the general population when occurring in lean subjects. By including obesity, the prevalence jumps up to 64 %. Naturally, one may think, that the insulin resistance syndrome that accompanies obesity is different in origin and significance from that observed in the lean, as Dr. Turner and colleagues infer from their own data in a population of Type 2 Letters to the editor diabetic patients [3] . We tend to agree on this, and the final point therefore is that a better understanding is needed of the origin, pathogenetic impact, and prognostic value of reduced insulin sensitivity in non-obese individuals. 
